Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

D1010000

Dibutyl phthalate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

n-Butyl phthalate, DBP, Phthalic acid dibutyl ester

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
C6H4-1,2-[CO2(CH2)3CH3]2
CAS Number:
84-74-2
Molecular Weight:
278.34
Beilstein:
1914064
MDL number:
MFCD00009441
UNSPSC Code:
41116107
PubChem Substance ID:
329798660
NACRES:
NA.24

grade

pharmaceutical primary standard

vapor density

9.6 (vs air)

vapor pressure

1 mmHg ( 147 °C)

API family

dibutyl phthalate

autoignition temp.

756 °F

expl. lim.

0.47 %, 236 °F

manufacturer/tradename

EDQM

refractive index

n20/D 1.492 (lit.)

bp

340 °C (lit.)

mp

−35 °C (lit.)

density

1.043 g/mL at 25 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCCCOC(=O)c1ccccc1C(=O)OCCCC

InChI

1S/C16H22O4/c1-3-5-11-19-15(17)13-9-7-8-10-14(13)16(18)20-12-6-4-2/h7-10H,3-6,11-12H2,1-2H3

InChI key

DOIRQSBPFJWKBE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Plasticizer

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Health hazardEnvironment
GHS08,GHS09

Signal Word

Danger

Hazard Statements

H360FD - H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 2 - Repr. 1B

Storage Class Code

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

367.7 °F - open cup

Flash Point(C)

186.5 °C - open cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Harpreet Bhatia et al.
Aquatic toxicology (Amsterdam, Netherlands), 149, 103-115 (2014-03-01)
Phthalic acid esters (PAEs) are a class of synthetic industrial chemicals commonly found in the aquatic environment worldwide. PAEs have been recognised as anti-androgens in male mammals but little is known about their endocrine disrupting effects in fish. This study
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
Luciano Candilio et al.
Heart (British Cardiac Society), 101(3), 185-192 (2014-09-26)
Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service